Time to recovery – Page 3 – Communicable Diseases Research

Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial

Research article

Published on 2021-10-272022-10-05
Journal: EClinicalMedicine [Category] 신약개발, 임상,

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials

COVID-19에 대한 Janus kinase inhibitors의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-10-012022-09-11
Journal: International immunopharmacology [Category] SARS, 신약개발, 임상,

[키워드] 95% CI adverse event all-cause mortality rate And tofacitinib Baricitinib clinical Clinical efficacy Clinical outcome clinical recovery ClinicalTrials Control Controlled controlled trials controls COVID-19 COVID-19 patients Efficacy and safety hospitalized COVID-19 patients inception inhibitor Invasive mechanical ventilation Jak JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitor Kinase inhibitor Meta-analysis mortality rate no significant difference Placebo Primary outcome Randomized controlled trial Randomized controlled trials RCT RCTs receiving risk ruxolitinib Safe searched Serious Adverse Event Serious Adverse Events standard care systematic review the patient Time to recovery Tofacitinib treating COVID-19 patient Treatment
[DOI] 10.1016/j.intimp.2021.108027 PMC 바로가기 [Article Type] Meta-Analysis

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

SARS-CoV-2 스파이크 수용체 결합 단백질에 대한 중화 단일클론항체 CT-P59의 안전성, 바이러스학적 효능 및 약동학: 건강한 개인 및 경증 SARS-CoV-2 환자를 대상으로 한 무작위, 위약 대조, 1상 연구 2건 전염병

Randomized Controlled Trial

Published on 2021-10-012022-09-12
Journal: Clinical therapeutics [Category] MERS, SARS, 임상, 진단,

[키워드] Adverse adverse event AEs Against antibody Antiviral C-reactive protein cellular entry Clinical efficacy Cohort Common Terminology Criteria COVID-19 CT-P59 dose double-blind elevated end point enrolled examined exhibited headache healthy in healthy individual individual mild SARS-CoV-2 infection monoclonal monoclonal antibody Neutralizing neutralizing monoclonal antibody pathologic Patient pharmacokinetic pharmacokinetics phase Placebo placebo-controlled Pyrexia Randomized receive receiving reduce reductions in regdanvimab reported Safety safety profile SARS-CoV-2 secondary single ascending dose spike Time to recovery Tolerability viral titer
[DOI] 10.1016/j.clinthera.2021.08.009 PMC 바로가기 [Article Type] Randomized Controlled Trial

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

영국 지역 사회에서 합병증의 위험이 높은 사람들의 Covid-19에 대한 흡입 부데소니드 (원칙) : 무작위, 제어, 오픈 라벨, 적응 형 플랫폼 시험

Randomized Controlled Trial

Published on 2021-09-042022-08-13
Journal: Lancet (London, England) [Category] MERS, SARS, 임상,

[키워드] absolute difference Adaptive platform trial Admission analysed assigned Bayesian credible interval Bayesian models BCI benefit Budesonide chance Community Comorbidities Complication complications COVID-19 COVID-19 in patient credible interval death Effectiveness Efficacy eligible Eligible participants Endpoint enrolment estimated rate finding funding greater hazard ratio high risk higher risk hospital Hospital admission Hospital admissions IMPROVE include individual inhaled budesonide inhaled budesonide reduce Innovation ISRCTN ISRCTN registry multi-arm multicentre Odds ratio Older Open-label other treatment other treatments outcome participant people with COVID-19 Platform trial primary analysis primary analysis population primary care Probability randomisation randomised Randomly receiving reducing Registered SARS-CoV-2-positive participant SARS-CoV-2-positive participants Serious Adverse Event Serious Adverse Events superiority criterion threshold Time to recovery Trial United Kingdom usual care usual care alone usual care group
[DOI] 10.1016/S0140-6736(21)01744-X PMC 바로가기 [Article Type] Randomized Controlled Trial

Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019

Research Articles

Published on 2021-09-032022-10-30
Journal: Intensive Care Medicine Experimental [Category] COVID-19,

[키워드] activated age analyzed ARDS association Cell Cohort coronavirus disease COVID-19 cytotoxicity Defense died ECMO expression extracorporeal membrane oxygenation Factor Genotype ICU independent innate immune intensive care intensive care unit invasive mechanical investigated Killer immunoglobulin-like receptor KIR KIR2DS5 median MHC-I moderate natural NK cell NK cells outcome Patient patients with COVID-19 patients with moderate promote receptor required Result risk factor SARS-CoV-2 severe ARDS severe coronavirus disease severe COVID-19 significantly significantly higher supplementary material target cells Time to recovery transfer treated validation cohort viral infection
[DOI] 10.1186/s40635-021-00409-4 PMC 바로가기 [Article Type] Research Articles

A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management

Research article

Published on 2021-09-012022-10-05
Journal: Annals of Medicine and Surgery [Category] 신약개발, 임상, 치료제,

[키워드] adjusted age anti-parasitic drug Antiviral Antiviral effect antiviral medicine Care caused clinical benefit clinical trial Comorbidities Comorbidity Control control group COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients cured death Diabetes Mellitus drug Effectiveness Endpoint experimental group Gender hospital incidence increased the risk less male management measure Niclosamaide niclosamide Older open label pandemic Patient per day randomised controlled trial reduced Result risk SARS-CoV-2 SARS-CoV2 Side effect significant difference significantly Standard of care study group survival therapeutic effect therapy Time to recovery took place treat treated Treatment viral infections
[DOI] 10.1016/j.amsu.2021.102779 [Article Type] Research article

COVID-19 article altimg-small=kintcovid_s.svg altimg=kintcovid_o.svg>Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Research article

Published on 2021-09-012022-10-05
Journal: Kidney International Reports [Category] 치료제,

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

영국에서 역효과 위험이 높은 사람들을 대상으로 코로나19가 의심되는 지역사회 치료를 위한 독시사이클린(원칙): 무작위, 통제, 공개, 적응 플랫폼 시험

Randomized Controlled Trial

Published on 2021-09-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 치료법,

[키워드] absence adaptive Adaptive platform trial adaptive randomisation adverse outcome adverse outcomes age analysed assigned Asthma Bayesian BCI benefit body-mass body-mass index clinical trial clinical trials clinically Community Comorbidities Comorbidity contributed COVID-19 credible interval criterion death defined Department diabetes disease doxycycline Efficacy Endpoint enrolled Evidence evidence of female FIVE Follow-up greater groups hazard ratio heart disease hepatic impairment high risk Hospital admission Hospital admissions hospitalisation hypertension Innovation Intention intention to treat interval Intervention ISRCTN Lung disease male manuscript median time Mild multi-arm National neurological obesity occurred Older once daily Open-label participant participants randomly assigned Patient platform Platform trial positive PCR test primary analysis primary care principle Probability randomisation randomised Randomised trial Randomly reductions in Registered reported respiratory symptom respiratory symptoms SARS-COV-2 infection stroke Support the mean Time to recovery treat treating COVID-19 Treatment treatment for COVID-19 Trial usual care weakened immune system
[DOI] 10.1016/S2213-2600(21)00310-6 PMC 바로가기 [Article Type] Randomized Controlled Trial

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

중증 COVID-19 감염 환자에서 Favipiravir 대 표준 치료: 후향적 비교 연구

Article

Published on 2021-09-012022-09-11
Journal: Journal of infection and public health [Category] Coronavirus, SARS, 치료제,

Prevalence and Prognostic Value of Myocardial Injury in the Initial Presentation of SARS-CoV-2 Infection among Older Adults

Article

Published on 2021-08-232022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,